Optimizing Protein Expression

Driving Results with Smarter Strategies

6-7 November 2013

Preliminary Agenda

The expression of proteins for characterization and therapeutics has grown dramatically over the last 2 decades. However, the higher demand for larger amounts of protein, in shorter periods of time continue to plague protein researchers. It is crucial to increase the throughput of expression, production and purification processes. Sometimes this requires new technologies and strategies, other times it requires a re-working or re-engineering of existing resources to improve outcomes. In addition, success demands making wise and effective choices in the selection of the host for protein expression. This second part of the protein expression stream for PEGS Europe will focus on the methods and technologies for achieving the highest possible yield, with the best functionality. 


STRATEGIES FOR SUCCESS FROM THE BEGINNING 

Toward System-Level Understanding of Baculovirus-Host Cell Interactions: From Molecular Fundamental Studies to Large-Scale Proteomics Approaches

Paula M. Alves, Ph.D., Director, Animal Cell Technology Unit, Instituto de Biologia Experimental e Tecnológica Oeiras, Portugal

Optimizing Heterologous Protein Production in the Periplasm of E. coli

Jan-Willem de Gier, Ph.D., Associate Professor, Center for Biomembrane Research, Stockholm University; CSO, Xbrane Bioscience AB


CELL LINE CHOICES 

Use of an Anti-Apoptotic CHO Cell Line for Transient Gene Expression

Athena Wong, Ph.D., Scientist, Early Stage Cell Culture, Genentech

Generation and Optimization of a Suspension CHO-EBNA Expression System to Express Multiple Different Classes of Proteins

Robert Roth, Ph.D., Reagents and Assay Development, AstraZeneca, Sweden


SOLVING PROBLEMS IN EXPRESSION AND STABILIBITY 

GlycoDelete Technology: Shortcutting Mammalian Cell N-glycosylation to Produce Therapeutic Proteins with Simplified Sialylated N-glycans

Francis Santens, Researcher, Department for Molecular Biomedical Research, VIB

Mammalian Stable Expression of Biotherapeutics

Thomas Jostock, Ph.D., Novartis Pharma AG, Basel

Production of Minicircles for Gene Therapy and Transient Protein Expression

Michaela Simcikova, Center for Biological and Chemical Engineering, IBB-Institute for Biotechnology and Bioengineering, Instituto Superior Técnico